» Articles » PMID: 12461352

Treatment of Osteonecrosis with Autologous Bone Marrow Grafting

Overview
Publisher Wolters Kluwer
Specialty Orthopedics
Date 2002 Dec 4
PMID 12461352
Citations 232
Authors
Affiliations
Soon will be listed here.
Abstract

Core decompression with bone graft is used frequently in the treatment of osteonecrosis of the femoral head. Many different techniques have been described. In the current series, grafting was done with autologous bone marrow obtained from the iliac crest of patients operated on for osteonecrosis of the hip. The results of a prospective study of 189 hips in 116 patients treated with core decompression and autologous bone marrow grafting are reported. Patients were followed up from 5 to 10 years. The outcome was determined by the changes in the Harris hip score, by progression in radiographic stages, and by the need for hip replacement. The bone marrow was harvested with the patient under general anesthesia. The usual sites were the anterior iliac crests. The aspirated marrow was reduced in volume by concentration and injected into the femoral head after core decompression with a small trocar. When patients were operated on before collapse (Stage I and Stage II), hip replacement was done in nine of the 145 hips. Total hip replacement was necessary in 25 hips among the 44 hips operated on after collapse (Stage III and Stage IV). To measure the number of progenitor cells transplanted, the fibroblast colony forming unit was used as an indicator of the stroma cell activity. Patients who had the greater number of progenitor cells transplanted in their hips had better outcomes.

Citing Articles

Personalizing core decompression grafting technique for osteonecrosis of the femoral head: calculating the volume of bone resected and adjunct volume required to fill the defect.

Bergemann R, Massey A, Tommasini S, Wiznia D J Orthop Surg Res. 2025; 20(1):229.

PMID: 40033401 PMC: 11874654. DOI: 10.1186/s13018-025-05606-5.


Is core decompression and bone marrow concentrate with demineralized bone matrix and platelet-rich fibrin suitable for treating femoral head osteonecrosis?.

Cevolani L, Focaccia M, Spazzoli B, Bruschi A, Staals E, Dozza B J Hip Preserv Surg. 2025; 11(4):263-270.

PMID: 39839553 PMC: 11744473. DOI: 10.1093/jhps/hnae031.


Orthobiologic therapies delay the need for hip arthroplasty in patients with avascular necrosis of the femoral head: A systematic review and survival analysis.

Zaffagnini M, Boffa A, Andriolo L, Raggi F, Zaffagnini S, Filardo G Knee Surg Sports Traumatol Arthrosc. 2024; 33(3):1112-1127.

PMID: 39543728 PMC: 11848991. DOI: 10.1002/ksa.12532.


Translational horizons in stem cell therapy for osteonecrosis of the femoral head: a journey from basic research to clinical practice through bibliometric insights.

Wu T, Zhou Y, Shi W, Guo S, Tian H, Li W J Transl Med. 2024; 22(1):982.

PMID: 39478610 PMC: 11523765. DOI: 10.1186/s12967-024-05784-6.


Evolution and Innovations in Bone Marrow Cellular Therapy for Musculoskeletal Disorders: Tracing the Historical Trajectory and Contemporary Advances.

Lana J, de Brito G, Kruel A, Brito B, Santos G, Caliari C Bioengineering (Basel). 2024; 11(10).

PMID: 39451354 PMC: 11504458. DOI: 10.3390/bioengineering11100979.